For ADSTILADRIN patients, Ferring offers an excellent support mechanism in the Ferring Patient Assistance Program, which can even help determine how to navigate the financial aspects of bladder …

Dec 9, 2024 · Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. Includes …

Here are a few quick facts about ADSTILADRIN to help you get started. 75% About 3 out of 4 people with bladder cancer have NMIBC. For early-stage bladder cancer, BCG is a common first therapy. …

ADSTILADRIN® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS ...

Sep 12, 2023 · Urologists treating eligible high-risk bladder cancer patients at participating early experience program clinics in the U.S. can now prescribe the first and only FDA-approved …

Dec 16, 2022 · Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of …

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive …

Adstiladrin is also called nadofaragene firadenovec-vncg. Adstiladrin is a gene therapy that uses a non-replicating adenoviral vector (a modified virus that cannot multiply) to deliver a gene to bladder cells. …

Apr 1, 2025 · Abstract On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients …

ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive …